Åland Islands eye disease

Åland Islands eye disease (AIED), also known as Forsius-Eriksson syndrome or Forsius-Eriksson type ocular albinism, is a rare X-linked recessive eye disorder first described in a family from the Åland Islands in Finland. The condition primarily affects the eyes and is characterized by features that overlap with ocular albinism. Key clinical features include reduced visual acuity, nystagmus (involuntary rhythmic eye movements), foveal hypoplasia (underdevelopment of the central part of the retina responsible for sharp vision), hypopigmentation of the fundus (reduced pigmentation of the back of the eye), color vision deficiency (particularly protanopia or deuteranopia), and myopia (nearsightedness). Affected individuals may also demonstrate iris transillumination, where light passes through the iris due to reduced pigmentation. The disease predominantly affects males, while female carriers are typically asymptomatic or may show very mild signs. The condition results from mutations in the CACNA1F gene on the X chromosome, though the genetic basis has been debated historically and some overlap with incomplete congenital stationary night blindness (CSNB2) has been noted. Electroretinography (ERG) findings in affected individuals may show abnormalities consistent with dysfunction of retinal signaling pathways. There is currently no cure or specific treatment for Åland Islands eye disease. Management is supportive and focuses on optimizing visual function. This may include corrective lenses for refractive errors, low-vision aids, and tinted lenses or filters to help with light sensitivity. Regular ophthalmologic follow-up is recommended to monitor visual function over time. Genetic counseling is important for affected families to understand the inheritance pattern and recurrence risks.

Common questions about Åland Islands eye disease